Physician profile
Jared G Heiner
NPI 1710097068
$3,074.74
in general payments reported to CMS, 2019-2025
24 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $972 · 2021: $464 · 2022: $251 · 2023: $327 · 2024: $312 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $837.92 | 2020 | |
| Boston Scientific Corporation | $600.70 | 2019-2025 | Spaceoar Vue System - 10ml, Spaceoar System |
| Teleflex LLC | $239.04 | 2021-2023 | Urolift |
| Procept Biorobotics Corporation | $210.84 | 2022-2025 | |
| Abbvie INC. | $148.04 | 2020-2025 | |
| Astellas Pharma US INC | $147.96 | 2019-2023 | Myrbetriq |
| Allergan, INC. | $139.82 | 2019-2021 | |
| Janssen Biotech, INC. | $122.93 | 2019-2024 | Erleada, Akeega, Balversa |
| 180 Medical, INC. | $75.20 | 2021-2023 | Gentlecath Glide |
| Myovant Sciences INC. | $67.17 | 2021 | |
| Sumitomo Pharma America, INC. | $60.68 | 2023 | Gemtesa |
| Coloplast Corp | $56.19 | 2021-2023 | Titan |
| Endo Pharmaceuticals INC. | $50.98 | 2019-2021 | |
| Convatec INC. | $46.97 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $43.50 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.51 | 2021 | |
| Intuitive Surgical, INC. | $40.92 | 2022 | |
| Urogen Pharma, INC. | $34.42 | 2024 | |
| Telix Pharmaceuticals | $29.33 | 2024 | Illuccix |
| Myriad Genetic Laboratories, INC. | $27.23 | 2021-2023 | Prolaris |
| Dendreon Pharmaceuticals LLC | $15.63 | 2019 | |
| Pfizer INC. | $13.61 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $12.69 | 2021 | |
| Travere Therapeutics, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Heiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.